For research use only. Not for therapeutic Use.
Arformoterol Tartrate is an R,R enantiomer of formeoterol and agonist at β2-adrenergic receptors and TAS2Rs used to treat COPD. It induces airway relaxation, inhibits migration of human airway smooth muscle cells, and suppresses phosphorylation of JNK, p38 MAPK and the glucorticoid receptor.
| Catalog Number | R018091 |
| CAS Number | 200815-49-2 |
| Synonyms | N-[2-Hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]?ethyl]phenyl]formamide (+)-(2R,3R)-Tartaric Acid; (-)-Formoterol 1,2-Dihydroxyethane-1,2-dicarboxylic Acid; (R,R)-Formoterol Threaric Acid; Arformoterol d-Tartaric Acid; |
| Molecular Formula | C23H30N2O10 |
| Purity | ≥95% |
| Target | β2-adrenergic receptors agonist |
| Storage | -20°C |
| IUPAC Name | (2R,3R)-2,3-dihydroxybutanedioic acid;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide |
| InChI | InChI=1S/C19H24N2O4.C4H6O6/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-1(3(7)8)2(6)4(9)10/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2,5-6H,(H,7,8)(H,9,10)/t13-,19+;1-,2-/m11/s1 |
| InChIKey | FCSXYHUNDAXDRH-OKMNHOJOSA-N |
| SMILES | CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O.C(C(C(=O)O)O)(C(=O)O)O |
| Reference | </br>1:Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year. Donohue JF, Ganapathy V, Bollu V, Stensland MD, Nelson LM.Clin Ther. 2017 Jan;39(1):66-74. doi: 10.1016/j.clinthera.2016.11.021. Epub 2016 Dec 20. PMID: 28011247 </br>2:One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Donohue JF, Hanania NA, Make B, Miles MC, Mahler DA, Curry L, Tosiello R, Wheeler A, Tashkin DP.Chest. 2014 Dec;146(6):1531-42. doi: 10.1378/chest.14-0117. PMID: 25451347 Free PMC Article</br>3:Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD. Bollu V, Ernst FR, Karafilidis J, Rajagopalan K, Robinson SB, Braman SS.Int J Chron Obstruct Pulmon Dis. 2013;8:631-9. doi: 10.2147/COPD.S52557. Epub 2013 Dec 5. PMID: 24353413 Free PMC Article</br>4:Arformoterol tartrate in the treatment of COPD. Cazzola M, Hanania NA, Matera MG.Expert Rev Respir Med. 2010 Apr;4(2):155-62. doi: 10.1586/ers.10.16. Review. PMID: 20406080 </br>5:Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Madaan A.Drugs Today (Barc). 2009 Jan;45(1):3-9. doi: 10.1358/dot.2009.45.1.1313983. PMID: 19271027 </br>6:A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease. Kharidia J, Fogarty CM, Laforce CF, Maier G, Hsu R, Dunnington KM, Curry L, Baumgartner RA, Hanrahan JP.Pulm Pharmacol Ther. 2008 Aug;21(4):657-62. doi: 10.1016/j.pupt.2008.03.003. Epub 2008 Apr 7. PMID: 18501650 </br>7:Compatibility of arformoterol tartrate inhalation solution with three nebulized drugs. Bonasia P, Cook C, Cheng Y, Ong S.Curr Med Res Opin. 2007 Oct;23(10):2477-83. PMID: 17784997 </br>8:Arformoterol: (R,R)-eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, R,R-eformoterol, R,R-formoterol. [No authors listed]Drugs R D. 2004;5(1):25-7. Review. PMID: 14725487 |
